Skip to main content

Exact Sciences Value Stock - Dividend - Research Selection

Exact sciences

ISIN: US30063P1057 , WKN: 590273

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF

2025-12-17
Discover key risks of trading LABU ETF: understand leverage, compounding decay & why timing matters.

November $10B+ M&A Deals Set Q4 Up To Outpace Prior Quarter

2025-12-12
November's announced M&A deals of more than $10 billion in transaction value brought the fourth quarter's worldwide tally to 11 deals. Read more here.

Assessing Exact Sciences After 77.5% YTD Surge and Abbott Deal Outlook

2025-12-06
If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock has climbed to around $101.06, logging a powerful 45.1% gain over the last month and a 77.5% jump year to date, even though the last 5 years still show a -22.0% total return. Investors have been reacting to a steady stream of developments around Exact Sciences, including ongoing adoption of its...

Tempus AI: Revenue Mix and 2026 Growth Outlook Explained

2025-12-05
Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.

3 Overrated Stocks That Concern Us

2025-12-04
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report?

2025-12-03
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cathie Wood dumps $8.46 million in software giant

2025-12-01
Cathie Wood’s never been shy in rebalancing aggressively when she feels the market’s mispricing innovation, and her latest trades fit that description perfectly. The ARK Invest boss dumped nearly 855,000 GitLab (GTLB) stock in just a few days, which includes a massive 208,528-share sale on ...

This Top Dividend King Just Became an Even Better Buy

2025-11-30
The healthcare leader wants to make waves in a potentially highly lucrative market.

UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition

2025-11-29
Abbott Laboratories (NYSE:ABT) ranks among the best slow growth stocks to invest in. UBS reaffirmed its Buy rating and $158 price target for Abbott Laboratories (NYSE:ABT) on November 21 in response to the company’s agreed acquisition of Exact Sciences. In the largest acquisition in the medtech sector thus far this year, Abbott Laboratories (NYSE:ABT) signed […]

Exact Sciences (EXAS): Assessing Valuation After a 56% One-Month Rally

2025-11-25
Exact Sciences (EXAS) has been on the radar lately, with its stock showing solid momentum, up over 50% this past month. Recent trading has sparked fresh curiosity about its outlook and what could come next. See our latest analysis for Exact Sciences. Momentum is undoubtedly building for Exact Sciences, with the recent 56% surge in its 1-month share price return adding to a strong 83% total shareholder return over the past year. Investors seem to be responding to renewed optimism around the...